BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 27084918)

  • 1. Polymorphic substitution E157Q in HIV-1 integrase increases R263K-mediated dolutegravir resistance and decreases DNA binding activity.
    Anstett K; Cutillas V; Fusco R; Mesplède T; Wainberg MA
    J Antimicrob Chemother; 2016 Aug; 71(8):2083-8. PubMed ID: 27084918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity.
    Anstett K; Fusco R; Cutillas V; Mesplède T; Wainberg MA
    J Virol; 2015 Oct; 89(20):10482-8. PubMed ID: 26246578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.
    Liang J; Mesplède T; Oliveira M; Anstett K; Wainberg MA
    J Virol; 2015 Nov; 89(22):11269-74. PubMed ID: 26311878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity.
    Mesplède T; Osman N; Wares M; Quashie PK; Hassounah S; Anstett K; Han Y; Singhroy DN; Wainberg MA
    J Antimicrob Chemother; 2014 Oct; 69(10):2733-40. PubMed ID: 24917583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration.
    Mesplède T; Leng J; Pham HT; Liang J; Quan Y; Han Y; Wainberg MA
    mBio; 2017 Apr; 8(2):. PubMed ID: 28377526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The R263K substitution in HIV-1 subtype C is more deleterious for integrase enzymatic function and viral replication than in subtype B.
    Mesplède T; Quashie PK; Hassounah S; Osman N; Han Y; Liang J; Singhroy DN; Wainberg MA
    AIDS; 2015 Jul; 29(12):1459-66. PubMed ID: 26244385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to HIV Integrase Inhibitors: About R263K and E157Q Mutations.
    Charpentier C; Descamps D
    Viruses; 2018 Jan; 10(1):. PubMed ID: 29346270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.
    Oliveira M; Ibanescu RI; Anstett K; Mésplède T; Routy JP; Robbins MA; Brenner BG;
    Retrovirology; 2018 Aug; 15(1):56. PubMed ID: 30119633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The HIV-1 integrase E157Q polymorphism per se does not alter susceptibility to raltegravir and dolutegravir in vitro.
    Saladini F; Giannini A; Boccuto A; Tiezzi D; Vicenti I; Zazzi M
    AIDS; 2017 Oct; 31(16):2307-2309. PubMed ID: 28832412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant viruses.
    Pham HT; Mesplède T; Wainberg MA
    Retrovirology; 2016 Apr; 13(1):31. PubMed ID: 27130466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir.
    Quashie PK; Mesplède T; Han YS; Oliveira M; Singhroy DN; Fujiwara T; Underwood MR; Wainberg MA
    J Virol; 2012 Mar; 86(5):2696-705. PubMed ID: 22205735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness.
    Wares M; Mesplède T; Quashie PK; Osman N; Han Y; Wainberg MA
    Retrovirology; 2014 Jan; 11():7. PubMed ID: 24433497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dolutegravir resistance mutation R263K cannot coexist in combination with many classical integrase inhibitor resistance substitutions.
    Anstett K; Mesplede T; Oliveira M; Cutillas V; Wainberg MA
    J Virol; 2015 Apr; 89(8):4681-4. PubMed ID: 25653436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dolutegravir R263K resistance mutation in HIV-1 integrase is incompatible with the emergence of resistance against raltegravir.
    Oliveira M; Mesplède T; Moïsi D; Ibanescu RI; Brenner B; Wainberg MA
    AIDS; 2015 Nov; 29(17):2255-60. PubMed ID: 26372484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors.
    Hassounah SA; Mesplède T; Quashie PK; Oliveira M; Sandstrom PA; Wainberg MA
    J Virol; 2014 Sep; 88(17):9683-92. PubMed ID: 24920794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 Group O Resistance Against Integrase Inhibitors.
    Depatureaux A; Mesplède T; Quashie P; Oliveira M; Moisi D; Plantier JC; Brenner B; Wainberg MA
    J Acquir Immune Defic Syndr; 2015 Sep; 70(1):9-15. PubMed ID: 26017662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The G118R plus R263K Combination of Integrase Mutations Associated with Dolutegravir-Based Treatment Failure Reduces HIV-1 Replicative Capacity and Integration.
    Xiao MA; Cleyle J; Yoo S; Forrest M; Krullaars Z; Pham HT; Mesplède T
    Antimicrob Agents Chemother; 2023 May; 67(5):e0138622. PubMed ID: 37071019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1.
    Hassounah SA; Alikhani A; Oliveira M; Bharaj S; Ibanescu RI; Osman N; Xu HT; Brenner BG; Mesplède T; Wainberg MA
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study.
    Vavro C; Ruel T; Wiznia A; Montañez N; Nangle K; Horton J; Buchanan AM; Stewart EL; Palumbo P
    Antimicrob Agents Chemother; 2022 Jan; 66(1):e0164521. PubMed ID: 34694878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 Resistance to Dolutegravir Is Affected by Cellular Histone Acetyltransferase Activity.
    Anstett K; Brenner B; Mesplède T; Wainberg MA
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28835492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.